This component of the CRE-PF is a clinical trials network in Australia, called the ‘Pulmonary Fibrosis Australiasian Clinical Trials’ or PACT and is being led by Prof Daniel Chambers .
PACT will conduct randomized, controlled clinical trials to evaluate existing or new medications, combinations of medications, and defined management strategies for patients with PF.
The vision of PACT is to reduce the morbidity and mortality associated with pulmonary fibrosis and improve the quality of life for people living with pulmonary fibrosis, their carers and families in Australia through the facilitation and coordination of high quality clinical research.
The specific objectives of PACT are:
- Support investigator-driven pulmonary fibrosis research through: peer review, facilitating collaboration; streamlining HREC/governance approval processes.
- Engage with consumers to improve access to current information and increase awareness about pulmonary fibrosis clinical research in Australasia.
- Support pharma-sponsored pulmonary fibrosis research though: advocating for pulmonary fibrosis research to be conducted in Austalasia; assisting sponsors/CROs in identifying suitable sites
- Advocate for, and actively disseminate research outcomes/translate research into practice.
Determining the place of rehabilitation in PF care will act as an exemplar for PACT. We will conduct a world-first randomised controlled trial of pulmonary rehabilitation to improve quality of life for those with pulmonary fibrosis.
For further information about PACT, please go to the PACT website or contact Sandra Bancroft, PACT Coordinator at PACTCoordinator@cre-pf.org.au.